Comparison of combinations of drugs for treatment of obesity: Body weight and echocardiographic status

International Journal of Obesity

Volumn 31, Issue 5, 2007, Pages 850-857

  Whigham, L D ^a   Dhurandhar, N V ^a   Rahko, P S ^a   Atkinson, R L ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Obetech Obesity Research Center   (United States)

Author keywords

Cardiac valves; Co morbidities; Fenfluramine; Fluoxetine; Phentermine; Weight loss

Indexed keywords

FENFLURAMINE; FLUOXETINE; PHENTERMINE;

ADULT; AORTA VALVE REGURGITATION; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MITRAL VALVE REGURGITATION; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; WEIGHT REDUCTION;

ADULT; APPETITE DEPRESSANTS; BODY MASS INDEX; DRUG THERAPY, COMBINATION; FENFLURAMINE; FLUOXETINE; HEART VALVE DISEASES; HUMANS; MEDICAL RECORDS; OBESITY; PHENTERMINE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; WEIGHT LOSS;

EID: 34247544381     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803498     Document Type: Review

References (54)

1. Bray GA. Drug treatment of obesity. Am J Clin Nutr 1992; 55 (2 Suppl): 538S-544S.
2. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992; 51: 581-646.
3. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL. Long-term drug treatment of obesity in a private practice setting. Obes Res 1997; 5 : 578-586.
4. Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St John Sutton MG, Stunkard AJ et al. The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res 1998; 6: 278-284.
5. Dhurandhar NV, Blank RC, Schumacher D, Atkinson RL. Initial weight loss as a predictor of response to obesity drugs. Int J Obes Relat Metab Disord 1999; 23: 1333-13336.
6. Alger SA, Malone M, Cerulli J, Fein S, Howard L. Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. Obes Res 1999; 7 : 469-476.
7. Katz DA, Maloney MJ, Sutkamp JC, McConville BJ. Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. Int J Eat Disord 1999; 25: 469-474.
8. Kolotkin RL, Crosby RD, Williams GR, Hartley GG, Nicol S. The relationship between health-related quality of life and weight loss. Obes Res 2001; 9: 564-571.
9. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999; 7 : 523-531.
10. Steel JM, Munro JF, Duncan LJ. A comparative trial of different regimens of fenfluramine and phentermine in obesity. Practitioner 1973; 211: 232-236.
11. Hudson KD. The anorectic and hypotensive effect of fenfluramine in obesity. JR Coll Gen Pract 1977; 27: 497-501.
12. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2: 1142-1145.
13. Breum L, Astrup A, Andersen T, Lammert O, Nielsen E, Garby L et al. The effect of long-term dexfenfluramine treatment on 24-hr energy expenditure in man. A double-blind placebo controlled study. Int J Obesity 1990; 14: 613-621.
14. Mathus-Vliegen EMH, Van De Voore K, Kok AME, Res AMA. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake, and eating behaviour. J Intern Med 1992; 232: 119-127.
15. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263-270.
16. Lean MEJ. Sibutramine - a review of clinical efficacy. Int J Obesity 1997; 21: S30-S36.
17. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3 (Suppl 4): 553S-559S.
18. James WP, Avenell A, Broom J, Whitehead J. A one year trial to assess the value of orlistat in the management of obesity. Int J Obesity Relat Metab Disord 1997; 21 (Suppl 3): S24-S30.
19. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242.
20. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588.
21. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 635.
22. Kurz X, Van Ermen A. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 1772-1773.
23. Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine. N Engl J Med 1997; 337: 636.
24. Weissman NJ, Tighe Jr JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-release dexfenfluramine study group. N Engl J Med 1998; 339: 725-732.
25. Griffen L, Anchors M. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'. Arch Intern Med 1998; 158: 102.
26. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339: 713-718.
27. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Annals Intern Med 1998; 129: 870-874.
28. Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999; 7: 313-322.
29. Li R, Serdula MK, Williamson DF, Bowman BA, Graham DJ, Green L. Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy. Int J Obes Relat Metab Disord 1999; 23: 926-928.
30. Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999; 84: 1335-1338.
31. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999; 34: 1153-1158.
32. Teramae CY, Connolly HM, Grogan M, Miller Jr FA. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000; 75: 456-461.
33. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339: 719-724.
34. Rowland NE, Marshall M, Roth JD. Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats. Psychopharmacology (Berl) 2000; 149: 77-83.
35. Anchors M. Safer Than Phen-Fen. Prima Publishing: Rocklin, CA, USA, 1997.
36. Devlin MJ, Goldfein JA, Carino JS, Wolk SL. Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord 2000; 28: 325-332.
37. Reeve HL, Nelson DP, Archer SL, Weir EK. Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. Am J Physiol 1999; 276 (2 Part 1): L213-L219.
38. Bostwick JM, Brown TM. A toxic reaction from combining fluoxetine and phentermine. J Clin Psychopharmacol 1996; 16: 189-190.
39. Griffen L, Anchors M. The 'phen-pro' diet drug combination is not associated with valvular heart disease. Arch Intern Med 1998; 158: 1278-1279.
40. Atkinson RL, Russ CS, Ciavarella PA, Owsley ES, Bibbs ML. A comprehensive approach to outpatient obesity management. J Am Diet Assoc 1984; 84: 439-444.
41. Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November, 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 1061-1066.
42. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The evidence report. National Institutes of Health. Obes Res 1998; 6 (Suppl 2): 51S-209S.
43. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebocontrolled trial. Obes Res 2000; 8: 431-437.
44. Bowen RL, Atkinson RL. Addition of orlistat to long term phentermine treatment for obesity. Obes Res 2000; 8: 118.
45. Goldstein DJ, Rampey Jr AH, Dornseif BE, Levine LR, Potvin JH, Fludzinski LA. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes Res 1993; 1: 92-98.
46. Goldstein DJ, Rampey Jr AH, Roback PJ, Wilson MG, Hamilton SH, Sayler ME et al. Efficacy and safety of long-term fluoxetine treatment of obesity - maximizing success. Obes Res 1995; 3 (Suppl 4): 481S-490S.
47. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001; 62: 256-260.
48. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, et al., Goulder For The STORM Study Group M. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity Results from the European multi-centre STORM trial. sibutramine trial of obesity reduction and maintenance. Int J Obes Relat Metab Disord 2001; 25: 496-501.
49. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001; 161: 218-227.
50. Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65: 79-85.
51. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-2841.
52. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
53. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117: 870-874.
54. Ulus IH, Maher TJ, Wurtman RJ. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol 2000; 59: 1611-1621.